miR-126 expression patterns in human AML subtypes, its prognosis impact in t(8;21) AML, and its pathological effect in leukemogenesis induced by AE and AE9a fusion genes. Expression patterns of miR-126 in the In-house 85S data set (A) or the In-house 100S data set (B). The P values were calculated by 2-tailed Student t test. (C) Comparison of OS between t(8;21) AML patients with higher or lower levels of miR-126 expression (median OS, 1.9 years vs 7.0 years, respectively; P = .031) in the In-house 85S data set. Kaplan-Meier survival curves are shown. The P values were calculated by log-rank test. (D) Effect of miR-126 on AE- and AE9a-induced primary leukemogenesis. Kaplan-Meier curves are shown for 5 cohorts of transplanted mice: MSCV-PIG (control), MSCV-PIG-AML1-ETO (AE), MSCV-PIG-AML1-ETO-miR-126 (AE+miR-126), MSCV-PIG-AML1-ETO9a (AE9a), and MSCV-PIG-AML1-ETO9a-miR-126 (AE9a+miR-126). P values were calculated by log-rank test. (E) Expression of miR-126 level was detected by qRT-PCR assay in the primary BMT mouse BM cells, which were isolated and sorted by flow cytometry for CD45.2⁺ cells at the end point. **P < .01. (F) Wright-Giemsa–stained PB and BM, and H&E-stained spleen and liver of the primary BMT recipient mice at the end point. Bars represent 25 μm for PB and BM; 100 μm for spleen and liver. H&E, hematoxylin and eosin; _H, high; _L, low; n, number of mice studied; NC, normal hematopoietic cells; OS, overall survival; PB, peripheral blood; qRT-PCR, quantitative real-time polymerase chain reaction.